The AcuSure System for Patient Self-Testing is intended for the quantitative prothombin time testing of fresh, capillary whole blood by selected and suitably trained patients or their caregivers on the prescription of the treating physician. The AcuSure System for Patient Self-Testing is for the monitoring of patients on oral anticoagulant therapy and not intended to be used for screening purposes.

The AcuSure Pro System for Professional Use is intended for the quantitative prothrombin time testing of fresh, capillary whole blood by healthcare professionals. The AcuSure Pro System is for the monitoring of patients on oral anticoagulant therapy and not intended to be used for screening purposes.

Device Description

The AcuSure and AcuSure Pro test strips and meter measure capillary blood PT levels. When the sample is applied to the target area on the test strip, the meter detects the electrical drop between two electrodes on the test strip and begins the test. Inside the membrane of the test strip the red blood cells are separated from the plasma. The membrane also contains the reagents necessary to cause the coagulation reaction (clot formation) to occur. The thrombin, formed as part of the coagulation reaction, reacts with a reagent, which causes a fluorescent molecule to be released The time from the initial resistance drop to the onset of fluorescence is proportional to the prothrombin time of the sample.

AI/ML Overview

The provided text is a 510(k) summary for the Avocet AcuSure System. It describes the device, its intended use, and its substantial equivalence to a predicate device. However, it does not contain specific details about acceptance criteria, device performance studies, sample sizes, ground truth establishment, or any AI-related information.

Therefore, I cannot fulfill your request for the detailed table and study information as the input text does not include that data. The document focuses on regulatory approval and substantial equivalence rather than detailed performance metrics.

To answer your request, I would need a document that describes the clinical studies, their methodology, and results, including acceptance criteria and performance data.

Summary

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows a handwritten string of characters. The string appears to be "K99400b". The characters are written in a cursive style with varying stroke thicknesses.

Avocet Medical, Inc. Premarket Notification, 510(k), for the Avocet AcuSure System (for Patient Self-Testing) and the AcuSure Pro System (for Professional Use)

510(k) Summary

Introduction	According to the requirements of 21 CFR §807.92, the followinginformation provides sufficient detail to understand the basis for adetermination of substantial equivalence.
Submitter name,address, contact,date prepared	Avocet Medical, Inc.100 Great Oaks Blvd.San Jose, CA 95119(408)-574-6638Contact person: Jill FalconeDate Prepared: November 22, 1999
Device Name	Proprietary Name: Avocet AcuSure System (for Patient Self-Testing) and the Avocet AcuSure Pro System (for ProfessionalUse)Common Name: Prothrombin Time Test
Predicate Device	The AcuSure System (for patient self-testing) and the AcuSure ProSystem (for professional use) are exactly the same device exceptthat the AcuSure System (for patient self-testing) has labeling andquality control recommendations for the home user whereas theAcuSure Pro System has labeling and quality controlrecommendations for the professional user. The quality controland performance characteristics sections of the labeling for theAcuSure Pro System contain the same language that waspreviously cleared for professional use in 510(k)# K980839.
Device Description	The AcuSure and AcuSure Pro test strips and meter measurecapillary blood PT levels. When the sample is applied to the targetarea on the test strip, the meter detects the electrical drop betweentwo electrodes on the test strip and begins the test. Inside themembrane of the test strip the red blood cells are separated fromthe plasma. The membrane also contains the reagents necessary tocause the coagulation reaction (clot formation) to occur. Thethrombin, formed as part of the coagulation reaction, reacts with areagent, which causes a fluorescent molecule to be released The

{1}------------------------------------------------

time from the initial resistance drop to the onset of fluorescence is proportional to the prothrombin time of the sample. Intended Use The AcuSure System for Patient Self-Testing is intended for the quantitative prothombin time testing of fresh, capillary whole blood by selected and suitably trained patients or their caregivers on the prescription of the treating physician. The AcuSure System for Patient Self-Testing is for the monitoring of patients on oral anticoagulant therapy and not intended to be used for screening purposes. The AcuSure Pro System for Professional Use is intended for the quantitative prothrombin time testing of fresh, capillary whole blood by healthcare professionals. The AcuSure Pro System is for the monitoring of patients on oral anticoagulant therapy and not intended to be used for screening purposes. Comparison to Predicate Device The AcuSure System (for patient self-testing) and the AcuSure Pro System (for professional use) are substantially equivalent. The AcuSure System (for patient self-testing) and the AcuSure Pro System (for professional use) are exactly the same device except that the AcuSure System (for patient self-testing) has labeling and quality control recommendations for the home user whereas the AcuSure Pro System has labeling and quality control recommendations for the professional user. The quality control and performance characteristics sections of the labeling for the AcuSure Pro System contain the same language that was previously cleared for professional use in 510(k)# K980839.

{2}------------------------------------------------

Image /page/2/Picture/0 description: The image shows the seal of the Department of Health & Human Services (HHS). The seal features a stylized eagle with three lines forming its body and wings. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the eagle. The seal is black and white.

Ms. Jill Falcone Vice President of Regulatory Affairs and Quality Assurance Avocet Medical Incorporated 100 Great Oaks Boulevard San Jose, California 95119-1347

3 2000 FEB

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

Re: K994006

Trade Name: Avocet AcuSure System (for Patient Self-Testing) and the Avocet AcuSure Pro System (for Professional Use)

Regulatory Class: II Product Code: GJS Dated: November 11, 1999 Received: November 24, 1999

Dear Ms. Falcone:

We have reviewed your Section 510(k) notification of intent to market the Avocet AcuSure System (for Patient Self-Testing) and the Avocet AcuSure Pro System (for Professional Use) devices under a single 510(k) number as referenced above and we have determined that these two devices are substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). Please note that the consolidation of these two devices under a single 510(k) number, K994006, does not change the fact that there are two separate and different intended uses for these devices, one for professional use and one for home use by prescription, and two different sets of quality control recommendations for the two devices. You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, * and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895, A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (OS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic OS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

{3}------------------------------------------------

Page 2

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

Steven Autman

Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

INDICATIONS FOR USE STATEMENT

510(k) Number (if known): K 9940000

Device Names: Avocet AcuSure System for Patient Self-Testing and Avocet AcuSure Pro System for Professional Use.

Indications For Use:

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)
(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number	K994006

Prescription Use OR Over-The-Counter Use

(Per 21 CFR 801.109)

Over-
(Option

(Optional Format 1-2-96)

Regulation Number and Section

§ 864.7750 Prothrombin time test.

(a)
Identification. A prothrombin time test is a device used as a general screening procedure for the detection of possible clotting factor deficiencies in the extrinsic coagulation pathway, which involves the reaction between coagulation factors III and VII, and to monitor patients receiving coumarin therapy (the administration of one of the coumarin anticoagulants in the treatment of venous thrombosis or pulmonary embolism).(b)
Classification. Class II (performance standards).